| (Values in U.S. Thousands) | Apr, 2026 | Apr, 2026 | Apr, 2026 | Apr, 2026 | Apr, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Stada Arzneimittel Ag ADR (STDAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
STADA Arzneimittel AG was founded in Dresden on 1895. The Company's focus is on products with off-patent active pharmaceutical ingredients in the health care market; concentrating on the pharmaceutical market. It has two operating segments; Generics and Branded products. The Company's Branded Products include the cold medicine, Grippostad and Ladival, sun protection products, ApoGo, for parkinson's disease, Chondroxid, for the treatment of degenerative joint disease, Hirudoid, a venous therapeutic agent, Zaldar, pain medicine, Snup, nasal preparation and Levomecol, tropical antibiotic. The Company's Generic products include omeprazole, diclofenac, phospholipide, enalapril and pantoprazol. The Company's market regions are Germany, Central Europe, CIS/Eastern Europe and Asia & Pacific.